Topic
Antibody-Drug Conjugates (ADCs)
2 Podcasts on BackTable
Episode # 52 • 24 Mar 2026
Antibody Drug Conjugates Across the HER2 Spectrum: From HER2-Positive to Ultralow Breast Cancer
Antibody-drug conjugates (ADCs) are expanding treatment options in breast cancer, but their use requires careful attention to toxicity. In this episode of the BackTable Tumor Board Podcast, Dr. Kate Baker and Dr. Sara Nunnery review the role of ADCs in HER2-positive disease and their growing application in HER2-low and HER2-ultralow metastatic settings.
More on Antibody-Drug Conjugates (ADCs)
Loading recent podcasts…
Tumor Board Episode #52
Mar 24, 2026
with Dr. Sara Nunnery, Dr. Kate Baker
Antibody-drug conjugates (ADCs) are expanding treatment options in breast cancer, but their use requires careful...
140+ listens
Tumor Board Episode #48
Feb 17, 2026
with Dr. Erika Hamilton, Dr. Lindsay Peterson
In a patient with metastatic HER2-positive breast cancer, what should guide the next decision: trial data, toxicity, or...
240+ listens
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.